How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparators-simvastatin-and-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Comparators: simvastatin and ezetimibe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparators: simvastatin and ezetimibe (Comparators: simvastatin and ezetimibe) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin + ezetimibe combination. Area: Cardiovascular.

phase 3 Statin + ezetimibe combination HMG-CoA reductase (simvastatin); NPC1L1 transporter (ezetimibe) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Comparators: simvastatin and ezetimibe (Comparators: simvastatin and ezetimibe) — Organon and Co. This is a combination therapy using simvastatin (a statin that inhibits HMG-CoA reductase) and ezetimibe (which blocks cholesterol absorption in the intestine) to lower LDL cholesterol through dual mechanisms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparators: simvastatin and ezetimibe TARGET	Comparators: simvastatin and ezetimibe	Organon and Co	phase 3	Statin + ezetimibe combination	HMG-CoA reductase (simvastatin); NPC1L1 transporter (ezetimibe)
fluvastatin, ezetimibe	fluvastatin, ezetimibe	Novartis	phase 3	Statin + ezetimibe combination	HMG-CoA reductase; NPC1L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin + ezetimibe combination class)

Novartis · 1 drug in this class
Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparators: simvastatin and ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/comparators-simvastatin-and-ezetimibe. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing